Browse Technologies

Displaying 51 - 60 of 259


New antibiotics against new targets in multi-drug resistant microorganisms

New everninomicin antibiotics including a potent bifunctional antibiotic natural product targeting two different and distant ribosomal sites are under development and can be readily produced using synthetic biology. Developing resistance to this bidentate antibiotic should be very difficult for pathogenic microorganisms.


Licensing Contact

Jody Hankins

615.322.5907
Therapeutics
Infectious Disease

New Clostridium Difficile Recombinant Toxin for Safe Vaccine Development

A structural biology approach has identified a conserved region common to multiple Clostridium toxins. Specific mutations of the protein sequence in this region prevent the toxins from entering into intestinal cells, thereby preventing widespread tissue damage. These recombinant Clostridium toxins may be used to create a multivalent vaccine to protect against multiple species of Clostridium. Furthermore, the recombinant toxin may be used as a safer alternative to the native toxins in vaccine manufacturing. This discovery stems from a collaboration between the laboratories of Dr. Borden Lacy of Vanderbilt University and Dr. Roman Melnyk of the Hospital for Sick Children.


Licensing Contact

Jody Hankins

615.322.5907

New Drug for Blood Clot: FXII Inhibitors to Treat Thrombosis

Thrombosis is the formation of a blood clot inside a blood vessel, which may cause reduced blood flow to a tissue, or even tissue death. Thrombosis, inflammation, and infections are responsible for >70% of all human mortality. Thrombosis is also the major factor for heart disease and stroke. 500,000 die from thrombosis every year in Europe. Inhibitory treatment of these conditions may also improve the outcomes of several non-fatal diseases. Researchers from Vanderbilt University and Oregon Health & Science University have jointly discovered new monoclonal antibodies that potently inhibit the blood coagulation protein factor XII (FXII), a critical player in the pathway, and anticoagulate blood. This invention provides foundation for commercial development of anti-thrombotic drugs based on new molecular entities.


Licensing Contact

Janis Elsner

615.343.2430
Therapeutics

New Molecules Clear Chronic Infections by Disrupting Bacterial Energy Production Pathways

New compounds developed at Vanderbilt demonstrate a unique mechanism of broad spectrum activity to stymy antibacterial resistance. The compounds are particularly useful in chronic infections where long term antibiotic therapy fails, because it specifically kills "small colony variants" -- the bacteria that have developed resistance mechanisms. These compounds show promise in treating Methicillin-resistant S. aureus (MRSA), Bacillus anthracis (anthrax), and in overcoming difficult-to-treat infections in bone in cystic fibrosis patients. These compounds could be combined with new (and old) antimicrobial drugs to outwit resistant bacterial infections.


Licensing Contact

Karen Rufus

615.322.4295
Therapeutics

NMR Signal Amplification by Reversible Exchange (SABRE) in Water

Vanderbilt researchers have developed a method to perform the Parahydrogen Induced Polarization (PHIP) based method of Signal Amplification by Reversible Exchange (SABRE) in aqueous media. This allows the resulting hyperpolarized molecules to be used for in vivo applications.


Licensing Contact

Chris Harris

615.343.4433
Medical Imaging

Novel anti-platelet therapy for treatment of thrombosis, cardiovascular disease, and cerebrovascular injury

One of the leading causes of deaths in developed countries is related to thromboembolism. PAR-4 (protease activated receptor-4) is one of two receptors on the human platelet that respond to thrombin, the central enzyme of coagulation.  Researchers here at Vanderbilt University have developed novel antagonists of PAR-4 that could be beneficial for patients allowing for normal hemostasis during treatment for thrombotic events.


Licensing Contact

Tom Utley

615.343.3852
Therapeutics
Cardiovascular

Novel Target Regulating Angiogenesis

Vanderbilt scientists have discovered that the receptor tyrosine phosphatase DEP-1 plays a significant role in angiogenesis and that modulation of the DEP-1 receptor with certain agents can affect endothelial cell growth. The research team has developed antibodies that bind to the ectodomain of a mammalian transmembrane protein known as DEP-1 (for density enhanced protein) or CD148. CD148 (also named DEP-1/PTPn) is a receptor-like protein tyrosine phosphatase that is abundantly expressed in vascular endothelial cells, hematopoietic-cell lineages, duct epithelia of thyroid, mammary and gastrointestinal tissues.


Licensing Contact

Mike Villalobos

615.322.6751
Therapeutics

On Chip Polarimetry for HTS

Using microfluidic technology developed by the Bornhop Lab at Vanderbilt, this invention enables the rapid determination of the optical activity of compounds and solutions. Due to the nature of this invention, it is possible to screen a multitude of samples in a high throughput manner in less time with less material and greater accuracy than the industry standards.


Licensing Contact

Janis Elsner

615.343.2430
Research Tools

Organ-on-a-Chip System

Vanderbilt researchers have developed a group of microfluidic organ-on-chip devices that include perfusion controllers, microclinical analyzers, microformulators, and integrated microfluidic measurement chips. Together, these devices can measure and control multiple organ-on-chip systems in order to model the multi-organ physiology of humans.


Licensing Contact

Ashok Choudhury

615.322.2503
Microfluidics

Point of Care Rheological Assay for Sickle Cell Disease

Vanderbilt researchers have created a novel technology for the diagnosis and monitoring of disease states using the rheological properties of a blood sample with a lateral flow membrane.


Licensing Contact

Ashok Choudhury

615.322.2503